UCB and Biogen (BIIB) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a ...
Objectives Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) are associated with improved ...
Please provide your email address to receive an email when new articles are posted on . SLE-DAS remission and low disease activity discriminated between patients taking active drug vs. placebo. Both ...
Objective Outcome measures used in SLE randomised controlled trials (RCTs) have impeded trial success and drug approval. In ...
Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...
Findings showed a higher percentage of participants on obinutuzumab achieved a minimum 4-point improvement in SRI-4 at 52 weeks vs standard therapy. Topline data were announced from a phase 3 trial ...
In a new study, systemic lupus erythematosus (SLE) disease severity indicated by the presence of lupus nephritis, (LN, lupus-related kidney disease) and other SLE risk factors contributed to reduced ...
Assessing the severity of systemic lupus erythematosus (SLE) has been difficult due to the clinical variety of the disease. A new study, looked at circulating cell-free DNA (cfDNA) concentration in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results